NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.348) was uploaded to the NHS England Website on Wednesday 19, February 2025.
The following changes have been introduced:
Rucaparib (RUC4)
As maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy for a tumour which has a NEGATIVE status for a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation AND a NEGATIVE or UNKNOWN status for homologous recombination deficiency as defined by the presence of genomic instability where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Fedratinib (FED1)
For the treatment of patients with myelofibrosis previously treated with ruxolitinib where the following criteria have been met
Moved into routine commissioning - section B of list
Pembrolizumab in combination with chemotherapy (PEMB30)
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage or IIB or IIIA or N2 only IIIB non-small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met
Moved into routine commissioning - section B of list
Niraparib (NIR4)
Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation There is a separate form NIR3 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation
Treatment criterion (#11) updated
Durvalumab in combination with etoposide plus either carboplatin or cisplatin (DUR4)
For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met
Date moving into routine commissioning updated
Selpercatinib (SEL3)
Selpercatinib as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) exhibiting a RET gene fusion and who have previously received immunotherapy and/or platinum-based chemotherapy where the following criteria have been met
Date moving into routine commissioning updated